JPRN-UMIN000006410尚未招募未知
The efficacy of alternative regimen with dorzolamide/timolol fixed combination for glaucoma patients with combined use of the three separate components (prostaglandin analogue, beta-blocker and carbonic anhydrase inhibitor): a randomized, crossover trial. - The efficacy of alternative regimen with dorzolamide/timolol fixed combination for glaucoma patients with combined use of the three separate components (prostaglandin analogue, beta-blocker and carbonic anhydrase inhibitor): a randomized, crossover trial.
Department of Ophthalmology, Kanazawa University0 个研究点目标入组 40 人开始时间: 2011年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Pregnant and lactating women, the women who desired of the pregnancy. (2) Patients who have difficulty or are unable to undergo fundoscopy ( severe cataract, etc.). (3) Patients with active external ocular diseases, ocular inflammation or infection. (4) Patients with any corneal abnormality or other condition preventing reliable applanation tonometry. (5) Patients with history of refractive surgery, glaucoma surgery (SLT, trabeculotomy, trabeculectomy etc), vitreous surgery or retinal detachment surgery. (6) Patients with history of surgery for cataract within 3 months before the study. (7) Patients expected to require operation for an eye disease during the study period. (8) Patients with serious renal impairment (nephrotic syndrome, acute renal failure, chronic renal failure, etc.) (9) Patients with hepatic function disorder. (10) Patients with bronchial asthma or its history. (11) Patients with bronchospasm or serious chronic obstructive pulmonary disease. (12) Patients with cardiac failure, sinus bradycardia, atrioventricular block (second and third degrees), or cardiogenic shock. (13) Patients with right cardiac failure due to pulmonary hypertension. (14) Patients with congestive cardiac failure. (15) Patients with diabetic ketoacidosis and/or metabolic acidosis. (16) Patients with poorly controlled diabetes mellitus. (17) Patients with a anamnestic history of hypersensitivity to any ingredients of the investigational product. (18) Patients who has received administration of the adrenocortical steroid agent (except for local skin administration other than around eyes). (19) Patients whom doctor judged to be ineligible for this study.
研究者
相似试验
已完成
不适用
Evaluation of dorzolamide/timolol fixed-dose combination therapy for the patients who need more IOP (trough & peak) reduction under treatment of PG analoguesprimary open angle glaucoma and ocular hypertensionJPRN-UMIN000006828Hospital, University of the Ryukyus40
已完成
不适用
Evaluation of dorzolamide/timolol fixed-dose combination therapy for the patients who need more IOP (trough & peak) reduction under treatment of PG analogues and CAIGlaucomaJPRN-UMIN000006830Hospital, University of the Ryukyus20
已完成
不适用
Evaluation of dorzolamide/timolol fixed-dose combination therapy for the patients who need more IOP (trough & peak) reduction under treatment of PG analogues and beta-blockerGlaucomaJPRN-UMIN000006829Hospital, University of the Ryukyus20
已完成
不适用
Evaluation of dorzolamide/timolol fixed-dose combination therapy for the patients who need more IOP (trough & peak) reduction under treatment of PG analogues, beta-blocker and CAIJPRN-UMIN000006831Hospital, University of the Ryukyus20
已完成
不适用
Evaluation of dorzolamide/timolol fixed combination therapy for the patients who need more IOP reduction under PG analoguesprimary open angle glaucoma, ocular hypertensionJPRN-UMIN000004596Department of Ophthalmology, Kyoto Prefectural University of Medicine40